The pharmacokinetics of penicillamine in a female mongrel dog
dc.contributor.author | Bergstrom, Richard F. | en_US |
dc.contributor.author | Kay, Donald R. | en_US |
dc.contributor.author | Wagner, John G. | en_US |
dc.date.accessioned | 2006-09-11T15:38:57Z | |
dc.date.available | 2006-09-11T15:38:57Z | |
dc.date.issued | 1981-10 | en_US |
dc.identifier.citation | Bergstrom, Richard F.; Kay, Donald R.; Wagner, John G.; (1981). "The pharmacokinetics of penicillamine in a female mongrel dog." Journal of Pharmacokinetics and Biopharmaceutics 9(5): 603-621. <http://hdl.handle.net/2027.42/45080> | en_US |
dc.identifier.issn | 1573-8744 | en_US |
dc.identifier.issn | 0090-466X | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/45080 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=7334461&dopt=citation | en_US |
dc.description.abstract | The pharmacokinetic parameters of D-penicillamine were investigated by administering four intravenous bolus doses, four oral doses, and six constant rate intravenous infusions to a female mongrel dog at dosages comparable to 250, 500, 750, and 1000 mg in man. The pharmacokinetics of D-penicillamine demonstrated nonlinearity in the dog. There was more than proportional increase in the area under the whole blood concentration curve for an increase in the bolus intravenous dose. The steady state whole blood, plasma, and packed cell levels of penicillamine were increased more than proportionately for an increase in the intravenous infusion rate. Total body clearance of penicillamine was decreased by increasing the dose or the infusion rate of penicillamine. Correspondingly, the estimated half-life of unchanged penicillamine in the whole blood was decreased for increased intravenous bolus doses. The renal clearance of penicillamine was nonlinear, decreasing with time during the bolus experiments and increasing at higher infusion rates. The nonrenal clearance was decreased at higher infusion rates, suggesting that a saturable nonrenal elimination process exists for penicillamine in the dog. The nonlinearities that were observed in the dog, if also present in man, may be responsible in part for the dose related side effects reported clinically for penicillamine . | en_US |
dc.format.extent | 973954 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Kluwer Academic Publishers-Plenum Publishers; Plenum Publishing Corporation ; Springer Science+Business Media | en_US |
dc.subject.other | D-penicillamine Whole Blood and Plasma Concentrations | en_US |
dc.subject.other | Iv Bolus, Infusion, and Oral Administration of Penicil-lamine | en_US |
dc.subject.other | Biomedical Engineering | en_US |
dc.subject.other | Veterinary Medicine | en_US |
dc.subject.other | Pharmacology/Toxicology | en_US |
dc.subject.other | Biomedicine | en_US |
dc.subject.other | Pharmacy | en_US |
dc.subject.other | Biochemistry, General | en_US |
dc.subject.other | D-penicillamine Pharmacokinetics | en_US |
dc.subject.other | Rheumatoid Arthritis | en_US |
dc.subject.other | Bioavailability of Penicillamine | en_US |
dc.subject.other | Female Mongrel Dog | en_US |
dc.title | The pharmacokinetics of penicillamine in a female mongrel dog | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Pharmacy and Pharmacology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Rackham Arthritis Research Unit and Upjohn Center for Clinical Pharmacology, The University of Michigan, 48109, Ann Arbor, Michigan; Division of Immunology and Rheumatology, Department of Medicine, University of Missouri, Columbia, Missouri | en_US |
dc.contributor.affiliationum | College of Pharmacy and Upjohn Center for Clinical Pharmacology, The University of Michigan, 48109, Ann Arbor, Michigan; Lilly Research Laboratories, Lilly Laboratory for Clinical Research, Wishard Memorial Hospital, 46202, Indianapolis, Indiana | en_US |
dc.contributor.affiliationum | College of Pharmacy and Upjohn Center for Clinical Pharmacology, The University of Michigan, 48109, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 7334461 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/45080/1/10928_2005_Article_BF01061028.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/BF01061028 | en_US |
dc.identifier.source | Journal of Pharmacokinetics and Biopharmaceutics | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.